The White House says it has struck agreements with nine more pharmaceutical manufacturers to price drugs at 'most-favored-nation' levels, bringing the total to 26 companies covering, it claims, 89% of the branded drug market. The fact sheet says these companies have committed to invest at least $19.6 billion in U.S. manufacturing and that some will donate ingredients to a strategic reserve.
Beyond those figures, the sheet offers no independent verification of savings to actual patients, no timeline, and no explanation of how 'lowest price paid by other developed nations' will be enforced or audited. It instead pivots to declaring the actions 'decisive and historic' and asserting the administration is delivering wins 'the political establishment did not believe were possible' — a claim that is, notably, unfalsifiable and self-issued.
The full dispatch is available from the source below.